Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

@inproceedings{Lucas2019PharmacologicCI,
  title={Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients},
  author={Andrew Thomas Lucas and R. N. Robinson and Allison N. Schorzman and Joseph A. Piscitelli and Juan Razo and William C. Zamboni},
  year={2019}
}
The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components… CONTINUE READING
2
Twitter Mentions

Figures and Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 281 REFERENCES

Interspecies scaling: predicting clearance of anticancer drugs in humans

  • European Journal of Drug Metabolism and Pharmacokinetics
  • 1996
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

D. A. Reardon, A. B. Lassman, +7 authors J Fischer
  • Neuro-Oncology
  • 2017
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL